Revance Stock Loses 39% Of Its Value After FDA Rejects Its Frown Lines Injection

Revance Stock Loses 39% Of Its Value After FDA Rejects Its Frown Lines Injection

The FDA rejected Revance Therapeutics' frown lines treatment, depressing RVNC stock which fell to an 18-month low on Monday.